High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method

被引：70
作者：
Daneshtalab, N
Lewanczuk, RZ
Jamali, F [1 ]
机构：
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
[2] Univ Alberta, Dept Physiol, Edmonton, AB T6G 2N8, Canada
来源：
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2002年 / 766卷 / 02期
关键词：
valsartan;
D O I：
10.1016/S0378-4347(01)00507-2
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Purpose: To develop an easy assay for the quantitation of the angiotensin IT receptor antagonist valsartan in human plasma using a liquid extraction procedure. Method: The method involves acid extraction from 1 ml human plasma with methyl-tert.-butyl ether followed by back-extraction into a basic medium, An isocratic HPLC equipped with reverse phase column and a fluorescence detector was used at room temperature. Results: The response to 10-2000 ng/ml valsartan was linear, In plasma of three human subjects given 160 mg valsartan orally, concentrations of 25-1540 ng/ml were observed. Conclusion: This convenient method is suitable for pharmacokinetic studies of valsartan. (C) 2002 Published by Elsevier Science B.V.
引用
收藏
页码：345 / 349
页数：5
相关论文
共 8 条
[1]   Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist [J].
Criscione, L ;
Bradley, WA ;
Buhlmayer, P ;
Whitebread, S ;
Glazer, R ;
Lloyd, P ;
Mueller, P ;
deGasparo, M .
CARDIOVASCULAR DRUG REVIEWS, 1995, 13 (03) :230-250
[2]   Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man [J].
Flesch, G ;
Muller, P ;
Lloyd, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (02) :115-120
[3]   Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester [J].
Francotte, E ;
Davatz, A ;
Richert, P .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1996, 686 (01) :77-83
[4]   Screening for the detection of angiotensin-converting enzyme inhibitors, their metabolites, and AT II receptor antagonists [J].
Maurer, HH ;
Kraemer, T ;
Arlt, JW .
THERAPEUTIC DRUG MONITORING, 1998, 20 (06) :706-713
[5]   The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension [J].
Oparil, S ;
Dyke, S ;
Harris, F ;
Kief, J ;
James, D ;
Hester, A ;
Fitzsimmons, S .
CLINICAL THERAPEUTICS, 1996, 18 (05) :797-810
[6]   AUTOMATED-DETERMINATION OF AN ANGIOTENSIN-II RECEPTOR ANTAGONIST, CGP-48-933, IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
SIOUFI, A ;
MARFIL, F ;
GODBILLON, J .
JOURNAL OF LIQUID CHROMATOGRAPHY, 1994, 17 (10) :2179-2186
[7]   Pharmacokinetics, disposition and biotransformation of [C-14]-radiolabelled valsartan in healthy male volunteers after a single oral dose [J].
Waldmeier, F ;
Flesch, G ;
Muller, P ;
Winkler, T ;
Kriemler, HP ;
Buhlmayer, P ;
DeGasparo, M .
XENOBIOTICA, 1997, 27 (01) :59-71
[8]   Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy [J].
Wexler, RR ;
Greenlee, WJ ;
Irvin, JD ;
Goldberg, MR ;
Prendergast, K ;
Smith, RD ;
Timmermans, PBMWM .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :625-656
1